In an in vivo investigation using breast cancer orthotopic xenograft tumors, the administration of oleocanthal exhibited the capacity to stabilize E-cadherin while concurrently reducing vimentin expression in recurrent tumors derived from both BT-474 and MDA-MB-231. Here, VIM is linked to breast carcinoma.